Results 71 to 80 of about 69,426 (314)

Implementation Status and Challenges of Pharmacovigilance Program in Ethiopia: A Mixed-Methods Study

Inquiry: The Journal of Health Care Organization, Provision, and Financing
Functional pharmacovigilance systems are vital to ensure patient safety. There is a paucity of information on the organizational functionality of pharmacovigilance program in Ethiopia.
Sisay Endale Biru MSc, Tesfa Marew Wallelign MSc, Teferi Gedif Fenta PhD   +2 more
doaj   +1 more source

Strengthening adverse drug reaction reporting in Nepal

Asian Journal of Medical Sciences, 2015
Pharmacovigilance in Nepal is still in infancy. Till date only healthcare professionals are involved and the problem of underreporting is seen.
Nisha Jha
doaj   +1 more source

Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Levothyroxine (LT4) is the standard treatment for hypothyroidism and the most widely prescribed medication worldwide. Although generally safe, regulatory reports list potential cardiac, neuropsychiatric and musculoskeletal adverse events (AEs). Clarifying their clinical relevance is essential.
Bala Swetha Baskaran, Mohammad Ali Omrani, Flory T. Muanda   +2 more
wiley   +1 more source

What Affects the Quality of Pharmacovigilance? Insights From Qualitative Comparative Analysis

Pharmacology Research & Perspectives
Pharmacovigilance plays a significant role in guaranteeing the safety of medications for patients. Over the last three decades, China has significantly advanced its pharmacovigilance practices, yet the factors that drive the quality of pharmacovigilance ...
Yadong Wang, Yue Chen, Xingjuan Xu, Ting Ying, Runan Xia, Yuanyuan Zhang, Xuefeng Xie   +6 more
doaj   +1 more source

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database [PDF]

, 2013
Background: Drug-induced torsades de pointes (TdP) and related clinical entities represent a current regulatory and clinical burden. Objective: As part of the FP7 ARITMO (Arrhythmogenic Potential of Drugs) project, we explored the publicly available US ...
A Bate, A Clarke, A Pariente, AK Chung, Ariola Koci, B Darpo, BJ Drew, C Meyer-Massetti, DM Roden, DW Hough, E Poluzzi, E Poluzzi, E Poluzzi, E Raschi, E Raschi, Edoardo Spina, Elijah R. Behr, Elisabetta Poluzzi, Emanuel Raschi, EP Puijenbroek van, ER Behr, F Ponti De, F Ponti De, F Rani, Fabrizio De Ponti, GC Alexander, GK Isbister, H Verdoux, J Nielsen, J Papay, K Jolly, K Titier, LC Wittkampf, LS Schneider, Miriam Sturkenboom, NP Tatonetti, P Kannankeril, P Manu, P Vigneault, RC Owens Jr, RR Shah, S Dhillon, S Hennessy, S Kongsamut, S Leucht, SM Straus, Ugo Moretti, W Crumb, W Crumb, WA Ray, WA Ray, WJ Crumb Jr, WP Stephenson, Y Suzuki   +53 more
core   +4 more sources

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database

Clinical Pharmacology &Therapeutics, EarlyView.
Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal.
Hotaka Maruyama, Eiko Iwasa, Shinya Watanabe, Tomoaki Hasegawa, Kazuhiro Kajiyama, Taihei Tanaka   +5 more
wiley   +1 more source

Disclosure and adverse effects of complementary and alternative medicine used by hospitalized patients in the North East of England [PDF]

, 2012
Objectives: This study aimed to investigate the prevalence, disclosure and adverse effects of complementary and alternative medicine (CAM) use in hospitalised patients, and to explore the associations between patients’ perceived side-effects and relevant
Baqir, wasim, Bello, Nusirat, McGarry, Kenneth, Winit -Watjana, Win   +3 more
core   +2 more sources

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Strengthening Pharmacovigilance System to Capture Safety Data from HIV Clients on ART in Tanzania: Identification of Gaps in Safety Reporting System [PDF]

, 2013
In Tanzania, pharmacovigilance system is implemented by Tanzania Food and Drugs Authority (TFDA) that monitors drug use countrywide. TFDA is the main national custodian for recording, analyzing and disseminating safety information that is generated ...
Baraka, Vito, Fakih, Bakar, Francis, Filbert, Kabanywanyi, Abdulnoor, Maiga, Deo, Makunde, Williams, Massaga, Julius, Mmbando, Bruno, Msovela, Judith, Mushi, Adiel   +9 more
core  

Maternal RSV vaccination for infant protection: A systematic review and meta‐analysis of phase 3 trials with an integrated economic evaluation

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Background Respiratory syncytial virus (RSV) is a leading cause of hospitalization and mortality in early infancy. Maternal immunization offers a preventive strategy, but uncertainties regarding safety and economic value have limited its implementation.
Johnatan Torres‐Torres, Lourdes Rojas‐Zepeda, José Rafael Villafan‐Bernal, Raigam Martinez‐Portilla, Salvador Espino‐y‐Sosa, Pablo Cerda‐Flores, Elsa Romelia Moreno‐Verduzco, Irma Eloisa Monroy‐Muñoz, Ameyran Yolanda Gonzalez‐Guerrero, Juan Mario Solis‐Paredes, Javier Perez Duran   +10 more
wiley   +1 more source